
Ipsen
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
IPN | PA
Overview
Corporate Details
- ISIN(s):
- FR0010259150 (+17 more)
- LEI:
- 549300M6SGDPB4Z94P11
- Country:
- France
- Address:
- 65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT
- Website:
- https://www.ipsen.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Ipsen is a global biopharmaceutical company focused on developing and commercializing innovative medicines in specialty care. The company concentrates its efforts on three key therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Ipsen's strategy targets conditions with high unmet medical needs, leveraging its global infrastructure, scientific expertise, and strategic partnerships to accelerate its research pipeline and bring transformative treatments to patients worldwide. The company is committed to advancing science with the purpose of improving health outcomes for underserved patient populations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Date | Filing | Language | Size | Actions | |
---|---|---|---|---|---|
2025-10-07 18:30 |
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
French | 84.4 KB | ||
2025-10-07 18:30 |
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
|
English | 85.2 KB | ||
2025-09-30 18:30 |
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
|
English | 81.9 KB | ||
2025-09-30 18:30 |
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
English | 81.3 KB | ||
2025-09-16 18:30 |
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
English | 86.5 KB | ||
2025-09-16 18:30 |
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
|
English | 86.4 KB | ||
2025-09-02 18:00 |
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
English | 269.9 KB | ||
2025-09-02 18:00 |
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
|
English | 542.0 KB | ||
2025-07-10 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Ipsen - Juin 2025 - Information mensuelle relative au nombre total des droits d…
|
French | 124.2 KB | ||
2025-07-10 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Ipsen - June 2025 - Monthly information relative to the total number of voting …
|
English | 106.7 KB | ||
2025-07-01 09:00 |
Environmental & Social Information
Gemeinsam fur eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Communi…
|
German | 8.6 KB | ||
2025-06-17 18:00 |
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
|
English | 271.6 KB | ||
2025-06-17 18:00 |
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
English | 468.0 KB | ||
2025-06-13 18:00 |
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
|
English | 324.3 KB | ||
2025-06-13 18:00 |
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
English | 293.1 KB |
Automate Your Workflow. Get a real-time feed of all Ipsen filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Ipsen via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2024-09-04 | N/A | Other | Sell | 850 | 91,374.66 EUR |
2024-02-27 | N/A | Other | Buy | 500 | 51,916.20 EUR |
2023-07-31 | N/A | Other | Buy | 50,048 | N/A |